46.96
-0.27 (-0.57%)
| Penutupan Terdahulu | 47.23 |
| Buka | 47.47 |
| Jumlah Dagangan | 115,884 |
| Purata Dagangan (3B) | 1,021,664 |
| Modal Pasaran | 2,429,439,232 |
| Harga / Pendapatan (P/E TTM) | 22.58 |
| Harga / Pendapatan (P/E Ke hadapan) | 25.45 |
| Harga / Jualan (P/S) | 5.40 |
| Harga / Buku (P/B) | 5.72 |
| Julat 52 Minggu |
| Margin Keuntungan | 17.92% |
| Margin Operasi (TTM) | -9.46% |
| EPS Cair (TTM) | 1.12 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 17.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.98% |
| Nisbah Semasa (MRQ) | 4.11 |
| Aliran Tunai Operasi (OCF TTM) | 26.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 29.89 M |
| Pulangan Atas Aset (ROA TTM) | -5.20% |
| Pulangan Atas Ekuiti (ROE TTM) | 19.54% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | CareDx, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.38 |
|
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.22% |
| % Dimiliki oleh Institusi | 99.39% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |